CANF
$3.43
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead dru...
Recent News
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data
Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced pancreatic cancer patients, meeting the study's primary safety endpoint.
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Health care stocks were edging up late Friday afternoon with the NYSE Health Care Index and the Stat
Sector Update: Health Care Stocks Lower in Friday Afternoon Trading
Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the State Street H
Top Midday Stories: Nvidia-Groq Licensing Deal; Target Attracts Growing Interest From Toms Capital
All three major US stock indexes were edging lower in midday trading on Friday following the Christm
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as Investors Await Clues on Fed's Interest Rate Cut
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.6% and the actively tr